Bayer stock gains as Sunharbo wins first US approval

Bayer's U.S. regulatory milestone is moving into the commercial phase. The Food and Drug Administration approved Sunharbo, the brand name for asundexian, on November 9, 2026, and Bayer announced the decision on November 10. The company's release describes the drug as the first approved Factor XIa inhibitor in the United States.

Sunharbo is indicated with antiplatelet therapy for adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The recommended dose is 50 milligrams once daily. The approval gives Bayer a new product in secondary stroke prevention, an area where the company is seeking to strengthen its Pharmaceuticals business as established products mature.

Trial Results Support Approval

The approval rests on the Phase 3 OCEANIC-STROKE study, which randomized 12,327 patients after a non-cardioembolic ischemic stroke or high-risk TIA. Ischemic stroke occurred in 6.2 percent of patients receiving Sunharbo and antiplatelet therapy, compared with 8.4 percent in the placebo and antiplatelet group. Bayer reported a hazard ratio of 0.74 and a P value below 0.0001.

The safety profile remains central to the commercial outlook. Major bleeding was similar between the treatment and placebo groups at 1.6 and 1.5 events per 100 person-years, respectively. Gastrointestinal bleeding was higher with Sunharbo at 2.7 versus 2.1 events per 100 patient-years, and Bayer also reported increased hepatic enzymes among treated patients.

Commercial Launch Comes Next

Bayer expects shipments to begin in the United States in mid-to-late November, followed by availability for hospitals and pharmacies. The company is also seeking approvals in additional markets. As of November 2026, applications remained under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare, while China's National Medical Products Administration had approved asundexian on October 26.

Management presents the U.S. authorization as a first-in-class opportunity in cardiovascular medicine. The commercial execution will determine how quickly the regulatory success translates into revenue, with prescribing adoption, reimbursement and the safety profile likely to shape early demand. The company has not provided a revenue forecast for Sunharbo in the cited release.

Bayer stock traded at 56.68 euros on Lang & Schwarz at 10:12 CET on Friday, November 13, 2026, 0.21 percent above the Xetra close of Thursday, November 12, at 56.56 euros. The move places the shares near the level of the prior Xetra session while investors assess the launch potential of the new medicine.

Broader market sentiment remains relevant for German large-cap shares; follow the DAX for the wider market backdrop.

More news and analyses on Bayer stock.